Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors.


Journal

Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298

Informations de publication

Date de publication:
15 01 2019
Historique:
received: 27 09 2018
revised: 07 11 2018
accepted: 14 11 2018
pubmed: 16 12 2018
medline: 17 9 2019
entrez: 16 12 2018
Statut: ppublish

Résumé

A series of carbamate-based inhibitors of glutamate carboxypeptidase II (GCPII) were designed and synthesized using ZJ-43, N-[[[(1S)-1-carboxy-3-methylbutyl]amino]carbonyl]-l-glutamic acid, as a molecular template in order to better understand the impact of replacing one of the two nitrogen atoms in the urea-based GCPII inhibitor with an oxygen atom. Compound 7 containing a C-terminal 2-oxypentanedioic acid was more potent than compound 5 containing a C-terminal glutamic acid (2-aminopentanedioic acid) despite GCPII's preference for peptides containing an N-terminal glutamate as substrates. Subsequent crystallographic analysis revealed that ZJ-43 and its two carbamate analogs 5 and 7 with the same (S,S)-stereochemical configuration adopt a nearly identical binding mode while (R,S)-carbamate analog 8 containing a d-leucine forms a less extensive hydrogen bonding network. QM and QM/MM calculations have identified no specific interactions in the GCPII active site that would distinguish ZJ-43 from compounds 5 and 7 and attributed the higher potency of ZJ-43 and compound 7 to the free energy changes associated with the transfer of the ligand from bulk solvent to the protein active site as a result of the lower ligand strain energy and solvation/desolvation energy. Our findings underscore a broader range of factors that need to be taken into account in predicting ligand-protein binding affinity. These insights should be of particular importance in future efforts to design and develop GCPII inhibitors for optimal inhibitory potency.

Identifiants

pubmed: 30552009
pii: S0968-0896(18)31611-0
doi: 10.1016/j.bmc.2018.11.022
pmc: PMC6374116
mid: NIHMS1516502
pii:
doi:

Substances chimiques

Carbamates 0
Protease Inhibitors 0
ZJ43 0
Urea 8W8T17847W
Glutamate Carboxypeptidase II EC 3.4.17.21

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

255-264

Subventions

Organisme : NIA NIH HHS
ID : R01 AG057420
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH075673
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA161056
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH110246
Pays : United States
Organisme : NIMH NIH HHS
ID : P01 MH105280
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS093416
Pays : United States
Organisme : NIMH NIH HHS
ID : R25 MH080661
Pays : United States

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Références

Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):355-67
pubmed: 21460454
FEBS J. 2009 Aug;276(16):4448-62
pubmed: 19678840
Phys Rev Lett. 2003 Oct 3;91(14):146401
pubmed: 14611541
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
pubmed: 20057044
Nat Rev Drug Discov. 2005 Dec;4(12):1015-26
pubmed: 16341066
J Med Chem. 2004 Mar 25;47(7):1729-38
pubmed: 15027864
FEBS J. 2016 Jul;283(13):2528-45
pubmed: 27208881
Clin Cancer Res. 2008 May 15;14(10):3036-43
pubmed: 18483369
J Med Chem. 2004 Jul 1;47(14):3697-9
pubmed: 15214797
Chem Soc Rev. 2014 Jul 21;43(14):5032-41
pubmed: 24676339
J Med Chem. 2008 Dec 25;51(24):7737-43
pubmed: 19053759
Acta Crystallogr D Biol Crystallogr. 2004 Aug;60(Pt 8):1355-63
pubmed: 15272157
J Chem Inf Model. 2018 Jan 22;58(1):48-60
pubmed: 29182321
Biol Psychiatry. 2008 Jan 1;63(1):86-91
pubmed: 17597589
Eur J Nucl Med Mol Imaging. 2015 May;42(6):987-8
pubmed: 25573634
J Chem Phys. 2010 Apr 21;132(15):154104
pubmed: 20423165
Curr Med Chem. 2012;19(9):1282-94
pubmed: 22304717
FEBS J. 2007 Sep;274(18):4731-41
pubmed: 17714508
Brain Res. 2011 Jun 13;1395:62-73
pubmed: 21565332
Adv Pharmacol. 2016;76:215-55
pubmed: 27288079
EMBO J. 2006 Mar 22;25(6):1375-84
pubmed: 16467855
Biochemistry. 2009 May 19;48(19):4126-38
pubmed: 19301871
J Med Chem. 2001 Feb 1;44(3):298-301
pubmed: 11462970
J Nucl Med. 2017 Sep;58(Suppl 2):17S-26S
pubmed: 28864607
Curr Med Chem. 2012;19(9):1300-9
pubmed: 22304708
J Nucl Med. 2017 Sep;58(Suppl 2):67S-76S
pubmed: 28864615
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
J Med Chem. 2016 Jan 14;59(1):206-18
pubmed: 26629713
J Med Chem. 2011 Nov 10;54(21):7535-46
pubmed: 21923190
Mol Pain. 2008 Aug 01;4:31
pubmed: 18673570
Angiogenesis. 2016 Oct;19(4):487-500
pubmed: 27387982
JCI Insight. 2016 Aug 4;1(12):
pubmed: 27536732
J Neurochem. 2004 May;89(4):876-85
pubmed: 15140187
J Am Chem Soc. 2010 Sep 15;132(36):12711-6
pubmed: 20726553

Auteurs

Cyril Barinka (C)

Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252 50 Vestec, Czech Republic. Electronic address: cyril.barinka@ibt.cas.cz.

Zora Novakova (Z)

Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252 50 Vestec, Czech Republic.

Niyada Hin (N)

Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States.

Daniel Bím (D)

Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám. 2, Prague 6 166 10, Czech Republic.

Dana V Ferraris (DV)

McDaniel College, 2 College Hill, Westminster MD 21157, United States.

Bridget Duvall (B)

Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States.

Gabriel Kabarriti (G)

Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States.

Reiji Tsukamoto (R)

Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States.

Milos Budesinsky (M)

Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám. 2, Prague 6 166 10, Czech Republic.

Lucia Motlova (L)

Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252 50 Vestec, Czech Republic.

Camilo Rojas (C)

Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States; Department of Molecular and Comparative Pathobiology, Johns Hopkins University, Baltimore, MD 21205, United States.

Barbara S Slusher (BS)

Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States; Department of Neurology, Johns Hopkins University, Baltimore, MD 21205, United States.

Tibor András Rokob (TA)

Institute of Organic Chemistry, Research Centre for Natural Sciences, Hungarian Academy of Sciences, 1117 Budapest, Magyar Tudósok körútja 2, Hungary.

Lubomír Rulíšek (L)

Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám. 2, Prague 6 166 10, Czech Republic. Electronic address: lubomir.rulisek@uochb.cas.cz.

Takashi Tsukamoto (T)

Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States; Department of Neurology, Johns Hopkins University, Baltimore, MD 21205, United States. Electronic address: ttskuamoto@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH